Development and Validation of Gene Expression Profile Signatures in Early-Stage Breast Cancer

References

• Perou C. M., Sorlie T., Eisen M. B., et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797)747–752
   PubMed Web of Science ®Google Scholar
• Sorlie T., Perou C. M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98(19)10869–10874
   PubMed Web of Science ®Google Scholar
• Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100(14)8418–8423
   PubMed Web of Science ®Google Scholar
• Sotiriou C., Neo S. Y., McShane, L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100(18)10393–10398
   PubMed Web of Science ®Google Scholar
• Hu Z., Fan C., Oh D. S., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genom 2006; 7(1)96
   PubMedGoogle Scholar
• Eifel P., Axelson J. A., Costa J., et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. I Natl Cancer Inst 2001; 93(13)979–989
   PubMed Web of Science ®Google Scholar
• Goldhirsch A., Wood W. C., Gelber R. D., et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin Oncol 2003; 21(17)3357–3365
   PubMed Web of Science ®Google Scholar
• Goldhirsch A., Click I. H., Gelber R. D., et al. Meeting highlights: international expert con sensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16(10)1569–1583
   PubMed Web of Science ®Google Scholar
• Liu E. T. Mechanism-derived gene expression signatures and predictive biomarkers in clinical oncology. Proc Natl Acad Sci USA 2005; 102(10)3531–3532
   PubMed Web of Science ®Google Scholar
• van't Veer L.I., Dai H., van de Vijver M.I., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415(6871)530–536
   PubMed Web of Science ®Google Scholar
• van d e, Vijver, M.J., He Y. D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl I Med 2002; 347(25)1999–2009
   PubMed Web of Science ®Google Scholar
• Wang Y., Klijn J. G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365(9460)671–679
   PubMed Web of Science ®Google Scholar
• Foekens J. A., Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006; 24(11)1665–1671
   PubMed Web of Science ®Google Scholar
• Buyse M., Loi S., van't Veer , L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98(4)262–272
   PubMedGoogle Scholar
• Desmedt C., Piette F., Cardoso F., et al. TRANSBIG multi-centre independent validation of the Rotterdam 76-gene prognostic signature for patients with node-negative (N-) breast cancer (BC). 2006, Late Breaking News Abstract: Fifth European Breast Cancer Conference, Nice, France, March 21–24
   Google Scholar
• Klein C. A., Blankenstein T. J., Schmidt-Kittler, O., et al. Genetic heterogeneity of single dis seminated tumour cells in minimal residual cancer. Lancet 2002; 360(9334)683–689
   PubMed Web of Science ®Google Scholar
• Schmidt-Kittler O., Ragg T., Daskalakis A., et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 2003; 100(13)7737–7742
   PubMed Web of Science ®Google Scholar
• Chang H. Y., Sneddon J. B., Alizadeh A. A., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004; 2(2)E7
   PubMed Web of Science ®Google Scholar
• Chang H. Y., Chi J. T., Dudoit S., et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA 2002; 99(20)12877–12882
   PubMed Web of Science ®Google Scholar
• Chang H. Y., Nuyten D. S., Sneddon J. B., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 102(10)3738–3743
   PubMed Web of Science ®Google Scholar
• Lacroix M., Toillon R. A., Leclercq G. Stable “portrait” of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 2004; 11(3)497–522
   PubMed Web of Science ®Google Scholar
• Roylance R., Gorman P., Harris W., et al. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 1999; 59(7)1433–1436
   PubMed Web of Science ®Google Scholar
• Warnberg F., Nordgren H., Bergkvist L., et al. Tumour markers in breast carcinoma corre late with grade rather than with invasiveness. Br J Cancer 2001; 85(6)869–874
   PubMed Web of Science ®Google Scholar
• Elston C. W., Ellis I. O. Pathological prognostic factors in breast cancer. I. The value of his tological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 119: 403–410, 2002, 41(3A), 151
   Google Scholar
• Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: under standing the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98(4)262–272
   PubMed Web of Science ®Google Scholar
• Loi S., Haibe-Kains, B., Desmedt C., et al. Definition of clinically distinct subtypes within estrogen receptor positive breast carcinomas. J Clin Oncol, In press
   Web of Science ®Google Scholar
• Dai H., van't Veer L., Lamb J., et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005; 65(10)4059–4066
   PubMed Web of Science ®Google Scholar
• Oh D. S., Troester M. A., Usary J., et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006; 24(11)1656–1664
   PubMed Web of Science ®Google Scholar
• Sotiriou C., Wirapati P., Loi S., et al. Is genomic grade killing histological grading?, Oral Presentation Fifth European Breast Cancer Conference, Nice, France, March 21–24,2006
   Google Scholar
• Fan C., Oh D. S., Wessels L, et al. Different gene expression-based predictors for breast cancer patients are concordant. N Engl J Med 2006; 355(6)560–569
   PubMed Web of Science ®Google Scholar
• Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen treated, node-negative breast cancer. N Engl J Med 2004; 351(27)2817–2826
   PubMed Web of Science ®Google Scholar
• Pittman J., Huang E., Dressman H., et al. Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci USA 2004; 101(22)8431–8436
   PubMed Web of Science ®Google Scholar
• Galea M. H., Blarney R. W., Elston C. E., et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992; 22(3)207–219
   PubMed Web of Science ®Google Scholar
• Cronin M., Pho M., Dutta D., et al. Measurement of gene expression in archival paraffin- embedded tissues: development and performance of a 92-gene reverse transcriptase- polymerase chain reaction assay. Am J Pathol 2004; 164(1)35–42
   PubMed Web of Science ®Google Scholar
• Ayers M., Symmans W. F., Stec J., et al. Gene expression profiles predict complete patholo gic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophospha- mide chemotherapy in breast cancer. J Clin Oncol 2004; 22(12)2284–2293
   PubMed Web of Science ®Google Scholar
• Chang J. C., Wooten E. C., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362(9381)362–369
   PubMed Web of Science ®Google Scholar
• Chang J. C., Wooten E. C., Tsimelzon A., et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005; 23(6)1169–1177
   PubMed Web of Science ®Google Scholar
• Cleator S., Tsimelzon A., Ashworth A., et al. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Res Treat 2006; 95(3)229–233
   PubMed Web of Science ®Google Scholar
• Jansen M. P., Foekens J. A., van Staveren I.L., et al. Molecular classification of tamoxifen- resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005; 23(4)732–740
   PubMed Web of Science ®Google Scholar
• Ma X. J., Wang Z., Ryan P. D., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 6: 607–616
   Google Scholar